$775 Million is the total value of Johnson & Johnson Innovation - JJDC, Inc.'s 15 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GNCA | Exit | Genocea Biosciences, Inc. | $0 | – | -43,177 | -100.0% | -0.02% | – |
| PRVB | Exit | Provention Bio, Inc. | $0 | – | -574,973 | -100.0% | -1.48% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. | 7 | Q2 2021 | 74.6% |
| PROTAGONIST THERAPEUTICS INC. | 7 | Q2 2021 | 11.2% |
| BIOMX INC. | 7 | Q2 2021 | 8.1% |
| PHASEBIO PHARMACEUTICALS, INC. | 7 | Q2 2021 | 3.5% |
| ALDEYRA THERAPEUTICS, INC. | 7 | Q2 2021 | 1.2% |
| CASTLIGHT HEALTH INC. | 7 | Q2 2021 | 0.4% |
| SENSEONICS HOLDINGS, INC. | 7 | Q2 2021 | 0.2% |
| CATALYST BIOSCIENCES, INC. | 7 | Q2 2021 | 0.2% |
| TRACON PHARMACEUTICALS, INC. | 7 | Q2 2021 | 0.1% |
| MEIRAGTX HOLDINGS PLC | 6 | Q2 2021 | 21.2% |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-10 |
| 3 | 2024-04-10 |
| 4 | 2024-03-06 |
| 13F-NT | 2024-02-14 |
| 3/A | 2024-02-02 |
| 4/A | 2024-02-02 |
| SC 13G | 2023-11-16 |
| 13F-NT | 2023-11-09 |
| 3 | 2023-09-18 |
| 3 | 2023-09-18 |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.